Background: MicroRNAs (miRNAs) have been discovered to dictate the development of various tumors. However, studies on the roles of miRNAs in the progression of gastric cancer (GC) are still lacking. Methods: Herein, by analyzing GC cell lines and patients samples, we observed that miR-148b-5p was significantly downregulated in GC. We also confirmed that miR-148b-5p overexpression significantly inhibited GC cell proliferation and invasion in vitro and in vivo. Results: Overexpression of miR-148b-5p not only reprogrammed the metabolic properties of GC but also regulated the immune microenvironment by shifting lymphocyte and myeloid populations. Mechanistically, ATPIF1, an important glycolysis-associated gene, was identified as a direct target of miR-148b-5p and mediated the effect of miR-148b-5p. Notably, the low level of miR-148b-5p was significantly related with poor prognosis of GC patients (P < 0.001). Importantly, the levels of miR-148b-5p significantly changed the sensitivity of GC cells to several anti-cancer drugs (Doxorubicin, P < 0.05, Paclitaxel, P < 0.01, Docetaxel, P < 0.05). Conclusions: Targeting miR-148b-5p inhibits immunity microenvironment and gastric cancer progression.
Background: MicroRNAs (miRNAs) have been discovered to dictate the development of various tumors. However, studies on the roles of miRNAs in the progression of gastric cancer (GC) are still lacking. Methods: Herein, by analyzing GC cell lines and patients samples, we observed that miR-148b-5p was significantly downregulated in GC. We also confirmed that miR-148b-5p overexpression significantly inhibited GC cell proliferation and invasion in vitro and in vivo. Results: Overexpression of miR-148b-5p not only reprogrammed the metabolic properties of GC but also regulated the immune microenvironment by shifting lymphocyte and myeloid populations. Mechanistically, ATPIF1, an important glycolysis-associated gene, was identified as a direct target of miR-148b-5p and mediated the effect of miR-148b-5p. Notably, the low level of miR-148b-5p was significantly related with poor prognosis of GCpatients (P < 0.001). Importantly, the levels of miR-148b-5p significantly changed the sensitivity of GC cells to several anti-cancer drugs (Doxorubicin, P < 0.05, Paclitaxel, P < 0.01, Docetaxel, P < 0.05). Conclusions: Targeting miR-148b-5p inhibits immunity microenvironment and gastric cancer progression.
Authors: Newton A C S Wong; Fernanda Amary; Rachel Butler; Richard Byers; David Gonzalez; Harry R Haynes; Mohammad Ilyas; Manuel Salto-Tellez; Philippe Taniere Journal: J Clin Pathol Date: 2018-02-08 Impact factor: 3.411
Authors: René G Feichtinger; Daniel Neureiter; Tom Skaria; Silja Wessler; Timothy L Cover; Johannes A Mayr; Franz A Zimmermann; Gernot Posselt; Wolfgang Sperl; Barbara Kofler Journal: Oxid Med Cell Longev Date: 2017-06-28 Impact factor: 6.543
Authors: Patrícia M R Pereira; Komal Mandleywala; Ashwin Ragupathi; Lukas M Carter; Jeroen A C M Goos; Yelena Y Janjigian; Jason S Lewis Journal: J Nucl Med Date: 2019-06-06 Impact factor: 10.057